Status:

COMPLETED

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Lead Sponsor:

FibroGen

Collaborating Sponsors:

AstraZeneca

Conditions:

Anemia

Myelodysplastic Syndrome

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

PHASE3

Brief Summary

The objective of this study to evaluate the efficacy FG-4592 for the treatment of anemia in Chinese participants with lower risk MDS.

Detailed Description

This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each part, there is an up to 4 weeks screening period followed by a treatment period of 26 weeks and a 4 week follow-up per...

Eligibility Criteria

Inclusion

  • Key
  • Diagnosis of primary MDS classified as very low, low or intermediate risk with \<5% blasts (documented within 12 weeks prior to Day 1)
  • Screening Hb \<10 g/dL and ≥6g/dL
  • Transfusion independent defined as no red blood cell transfusions within 12 weeks of Day 1
  • Erythropoiesis-stimulating agent (ESA)-naïve (not within 30 days of Day 1)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
  • Key

Exclusion

  • Diagnosis of secondary MDS
  • Significant myelofibrosis (\>2+fibrosis)
  • Prior therapy with azacitidine, decitabine, antithymocyte globulin, cyclosporine, thalidomide, or lenalidomide within 12 weeks prior to Day 1
  • Baseline erythropoietin level of \>400 units (U)/liter (L)
  • Clinically significant anemia due to non-MDS etiologies
  • Note: Other inclusion and exclusion criteria may apply.

Key Trial Info

Start Date :

June 6 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 8 2023

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT03303066

Start Date

June 6 2018

End Date

February 8 2023

Last Update

May 3 2023

Active Locations (38)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (38 locations)

1

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

2

Anhui Provincial Hospital

Hefei, Anhui, China

3

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

4

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | DecenTrialz